Funding Round Supports Robotic Discovery Platform

A successful seed funding round of £3.2 million by Arctoris Ltd, developers of an automated, robotic laboratory dedicated to drug discovery, will be used to further build out the company’s commercial operations and service portfolio. The funding round was led by RT Partners and included angel investors Patrick Pichette and Vishal Gulati, as well as additional industry-recognised investors and advisors including Charles Songhurst, Alexander Straub, TD Veen AS and Tanarra Capital.

"At RT Partners, we invest in UK-based, IP-rich technology that has the potential to revolutionise the life science industry. Arctoris’s novel platform and compelling vision is perfectly aligned with this objective. The successful completion of this seed funding round will support the company’s clear potential to improve how drug discovery is planned and performed," said investor partner Alex Gough.

Martin-Immanuel Bittner MD DPhil, Chief Executive Officer and Co-Founder of Arctoris, commented: "This support from industry-recognised investors and advisors will enable our team to continue to develop our revolutionary approach to drug discovery, which has been specifically designed to produce data of the highest possible quality from a broad range of biochemical, molecular biology and cell biology assays. Through our platform, scientists and biotechnology entrepreneurs worldwide can make discoveries faster and more efficiently, paving the way to introducing new treatments to patients sooner."

"At a practical level, this funding will enable us to further advance our technology, expand our service offering, attract more leading experts to join our thriving team and support the imminent opening of our new, bespoke laboratory facility. It will also allow us to continue to be closely involved in BioTarget, the world’s first biotech competition for emerging companies dedicated to finding new molecules for cancer treatment," said Tom Fleming MChem, Chief Operating Officer and Co-Founder of Arctoris.

The success of the latest Arctoris funding round has also seen the company nominated as a "Seed-Stage Finance Raise of the Year" finalist at the 2019 European Lifestars Awards and a "BioSeed One to Watch Award" finalist at the 2019 OBN Awards ceremony. For more information on Arctoris, please visit www.arctoris.com